{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Cannata-Andia JB"],"pubmed_abstract":["<h4>Background</h4>Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus of cholecalciferol (100,000 IU) administered at hospital admission influences the outcomes of moderate-severe COVID-19 disease. In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed.<h4>Methods</h4>The COVID-VIT-D is a multicentre, international, randomised, open label, clinical trial conducted throughout 1 year. Patients older than 18 years with moderate-severe COVID-19 disease requiring hospitalisation were included. At admission, patients were randomised 1:1 to receive a single oral bolus of cholecalciferol (n=274) or nothing (n=269). Patients were followed from admission to "],"journal":["BMC medicine"],"pagination":["83"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8853840"],"repository":["biostudies-literature"],"pubmed_title":["A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial."],"pmcid":["PMC8853840"],"pubmed_authors":["Fernandez-Martin JL","Herrero-Puente P","Palomo-Antequera C","Cunningham J","Panizo S","Naves-Diaz M","Mouzo R","Ibanez GH","Pefaur-Penna J","Douthat W","Cannata-Andia JB","Sanchez-Polo V","Gomez-Alonso C","Gomez MD","Cusumano CA","Carrillo-Lopez N","Ballarino C","Maderuelo-Riesco I","Calvino-Varela J","Fernandez P","COVID-VIT-D trial collaborators","Diaz-Sottolano A"],"additional_accession":[]},"is_claimable":false,"name":"A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial.","description":"<h4>Background</h4>Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus of cholecalciferol (100,000 IU) administered at hospital admission influences the outcomes of moderate-severe COVID-19 disease. In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed.<h4>Methods</h4>The COVID-VIT-D is a multicentre, international, randomised, open label, clinical trial conducted throughout 1 year. Patients older than 18 years with moderate-severe COVID-19 disease requiring hospitalisation were included. At admission, patients were randomised 1:1 to receive a single oral bolus of cholecalciferol (n=274) or nothing (n=269). Patients were followed from admission to ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-31T01:19:27.324Z","creation":"2022-07-11T15:07:24.32Z"},"accession":"S-EPMC8853840","cross_references":{"pubmed":["35177066"],"doi":["10.1186/s12916-022-02290-8"]}}